9 / 11
Page 42
conferenceseries
.com
Volume 3
Journal of Cancer Diagnosis
Cancer Diagnostics Conference 2018
August 15-16, 2018
August 15-16, 2018 Singapore
International Conference on Cancer Research & Diagnostics
&
16
th
Asia Pacific Biotechnology Congress
Joint Event on
Rational combinations of active and passive immunotherapy mobilize immune and clinical
responses in terminal cancers
Run Sheng Ruan
1,2
and Qing Zhao Ruan
3
1
Xiamen University, China
2
Zhang Zhou Xin Pu Hospital, China
3
Harvard Medical School, USA
S
olid tumors encroach on the host’s immune microenvironment to favor its own proliferation. Strategies to enhance the
specificity of the endogenous T cell population against tumors have been met with limited clinical success. We aimed to
devise a 2-tier protocol coupling in vivo whole antigen priming with ex vivo cellular expansion to clinically evaluate survival in
patients following re-infusion of primed, autologous T cells, determining treatment efficacy. Treatment commenced with the
acquisition of whole tumor antigens from tumor cell lines corresponding with patients’ primary malignancy. Lysate mixture
was inoculated intradermally while Peripheral Blood Mononuclear Cells (PBMCs) were periodically extracted via phlebotomy
and expanded in culture ex vivo for re-infusion. Post treatment tumor-specific T cell response and cytotoxicity was confirmed
via ELISpot and Real-Time Cell Analyzing (RTCA) Assay. Serum cytokine levels and cytotoxicity scores were evaluated for
associations with survival status and duration. There was significant increase in cytotoxicity exhibited by T cells measured
using both ELISpot and RTCA following treatment. Correlation analysis determined significant association between higher
post treatment cytotoxicity scores and survival status (R=0.52, p=0.0028) as well as longer survival duration in months (R=0.59,
p=0.005). Our use of whole cell antigens proved effective in its task of in vivo priming, thereby greatly facilitating the ex vivo
cell expansion as previously noted. The unique PBMC culture system used in this study achieved over 85% CD8+ lymphocyte
concentration post expansion. The data showed a clear increase in tumor-specific cytotoxicity post treatment (p=0.037), which
directly translated to an improved survival rate both categorically (p=0.0028) as well as duration in months (p=0.005). This
same trend was backed up by the IFN-γ ELISpot count which demonstrated a positive association of the IFN- ELISpot score
with survival duration (p=0.04). In the future, dedicated studies in the recruitment of sufficient patients of specific cancers will
streamline this process and allow more in-depth analysis of post treatment changes segregated by each defined tumor cell line
chosen. Conduction of formal randomized controlled trials will be the direction to take in future studies.
rsruan@xmu.edu.cnJ Cancer Diagn 2018, Volume 3
DOI: 10.4172/2476-2253-C1-003